Novo Nordisk up 3% after Wegovy outperforms rivals in coronary heart illness trial
LONDON — Shares of Danish pharmaceutical large Novo Nordisk have been 3% larger in early offers Monday, after the corporate launched trial knowledge suggesting its blockbuster drug Wegovy outperforms main…